Muhammad Naufal Hibatullah

Muhammad Naufal Hibatullah

Auto-generated profile, based on publicly available information

Muhammad Naufal Hibatullah

Universitas Jember

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Narra J
Verified
Journal Article
Open access
PDF file
RRRauza Sukma Rita
Rauza Sukma Rita
KCKevin Nathaniel Cuandra
Kevin Nathaniel Cuandra
SNSyahidatul A. Nasri
Syahidatul A. Nasri
MCMutiara A. Carmenita
Mutiara A. Carmenita
NKNathania A. Kristaningtyas
Nathania A. Kristaningtyas
MTMuhammad Teguh
Muhammad Teguh
Diabetic kidney disease is a condition characterized by persistent albuminuria, diabetic glomerular lesions, and a reduced glomerular filtration rate in people with diabetes. Peptides in Cucumaria frondosa coelomic fluid have been proven to provide antidiabetic and anti-inflammatory activity that can be used as one of the innovations in developing a multitarget therapy, especially in diabetic kidney disease. Therefore, the aim of this study was to unravel the power of peptide-based metabolites from C. frondosa coelomic fluid as multitarget therapy for diabetic kidney disease using an in-silico study. UCSF Chimera software was utilized to construct the three-dimensional structure of coelomic fluid peptides from C. frondosa. The toxicity and allergenicity of peptides were examined using the ToxinPred and AllerTop websites, respectively. From the PDBJ database, the 3D structures of protein kinase B, alpha isoform (AKT1); vascular endothelial growth factor receptor 2 (VEGFR2); epidermal growth factor receptor (EGFR); α-glucosidase; and glucokinase were obtained. Molecular docking was carried out using MOE Software. In this in-silico study, peptide 9 (-10.32 kcal/mol), peptide 1 (-9.41 kcal/mol), and peptide 3 (-9.55 kcal/mol) were shown to act as specific adenosine triphosphate-competitive inhibitors of EGFR, AKT1, and VEGFR2, respectively. Peptide 8 (-11.06 kcal/mol) can specifically inhibit α-glucosidase by binding to its active site. Peptide 1 (-9.80 kcal/mol) is predicted to specifically inhibit glucokinase activity by blocking its active side. Molecular dynamics simulations confirmed stable interactions with receptor proteins. In conclusion, C. frondosa coelomic fluid peptides have been shown not only to alleviate diabetic kidney disease but also to stabilize blood glucose levels and prevent hyperglycemia based on in-silico analysis.

1 April 2025 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
BOBiomechy Oktomalioputri
Biomechy Oktomalioputri
KCKevin Nathaniel Cuandra
Kevin Nathaniel Cuandra
ARAldi Tamara Rahman
Aldi Tamara Rahman
ZAZaki S. Aaliyya
Zaki S. Aaliyya
ESEnrico F. Sihombing
Enrico F. Sihombing
SESelly Erwina
Selly Erwina
Context: Plasmodium knowlesi is an emerging zoonotic malaria species in Southeast Asia, challenging elimination efforts. Aims: To design a safe and immunogenic multi-epitope vaccine (MEV) targeting the merozoite surface protein-1 (MSP-1) of P. knowlesi using a comprehensive immunoinformatics approach. Methods: Conserved regions of the P. knowlesi MSP-1 sequence were retrieved and analyzed to predict helper T lymphocyte (HTL), cytotoxic T lymphocyte (CTL), and B cell epitopes. Epitopes were selected based on predicted immunogenicity, solubility, and safety. Suitable linkers were used to fuse selected epitopes, adjuvants, and sequences into a multi-epitope vaccine (MEV) construct. Physicochemical properties, immunogenicity, allergenicity, and antigenicity of the MEV were assessed in silico. Molecular docking and molecular dynamics (MD) simulation were conducted to evaluate MEV binding affinity and stability with toll-like receptor 4 (TLR4). The immunogenic potential was further evaluated using the C-ImmSim server to simulate host immune responses. Results: The 219-amino acid MEV construct was predicted to be stable, soluble, non-toxic, and non-allergenic, with 98.89% global population coverage. Molecular docking and MD simulations confirmed a stable interaction with TLR4. Immune simulation revealed efficient antigen clearance, significant production of IgM and IgG1/IgG2 antibodies, expansion of plasma and memory B cells, and activation of CD4⁺ and CD8⁺ T cells. A Th1-skewed cytokine response was observed, marked by elevated IFN-γ, IL-2, and IL-12 levels. Conclusions: The in silico-designed MEV demonstrated favorable immunological, structural, and population coverage profiles, supporting its potential as a promising vaccine candidate against P. knowlesi malaria. Further experimental validation is needed.

1 November 2024 in Molecular and Cellular Biomedical Sciences
Verified
Journal Article
Open access
PDF file
MHMuhammad Naufal Hibatullah
Muhammad Naufal Hibatullah
SSSuryono Suryono
Suryono Suryono
SRSheilla Rachmania
Sheilla Rachmania
Background: In acute coronary syndrome (ACS), antiplatelet therapy is crucial for inhibiting platelet aggregation. Dual antiplatelet therapy (DAPT) commonly employs aspirin along with clopidogrel, prasugrel, or ticagrelor. This is well known that aspirin acts as a cyclooxygenase (COX)-1 inhibitor, while clopidogrel, prasugrel, and ticagrelor act as P2Y12 inhibitors. Despite DAPT's proven efficacy in more effectively reducing cardiovascular events in ACS patients, this is associated with an increased risk of bleeding compared to mono antiplatelet therapy (MAPT). To minimize the cost and side effect that might arise from the use of DAPT, this is necessary to assess the potential of MAPT using a P2Y12 inhibitor drug, to understand whether they are capable of binding to both COX-1 and P2Y12. Hence, this study was conducted to identify P2Y12 inhibitor drugs that have the ability to bind to COX-1, allowing them to be proposed as MAPT.Materials and methods: Molecular docking was employed to assess binding affinity, interaction types, amino acid residues, binding distances, and visualizations in both 3D and 2D formats. The applications utilized were BIOVIA Discovery Studio and AutoDock, while the websites utilized were research collaboratory for structural bioinformatics protein data bank (RCSB PDB) and PubChem.Results: In silico findings reveal differences in binding strength among clopidogrel, prasugrel, and ticagrelor to COX-1 and P2Y12, with ticagrelor emerging as the stronger ligand due to a higher number of bindings and/or closer binding distances. Notably, only prasugrel and ticagrelor demonstrate the ability to bind to the active site of COX-1.Conclusion: Therefore, prasugrel and ticagrelor emerge as potential MAPT agents for ACS patients.Keywords: clopidogrel, prasugrel, ticagrelor, antiplatelet, ACS, in silico, molecular docking

12 February 2026 in Interventional Cardiology: Reviews, Research, Resources
Verified
Journal Article
Open access
SSSuryono Suryono
Suryono Suryono
MHMuhammad Farhan Hibatulloh
Muhammad Farhan Hibatulloh
ARAlfiyah Ramadhani
Alfiyah Ramadhani
CWCandra Agung Wibisana
Candra Agung Wibisana
ATAchmad Ilham Tohari
Achmad Ilham Tohari
HRHazbina Fauqi Ramadhan
Hazbina Fauqi Ramadhan
Background: Left main bifurcation lesions (LMBL) present considerable challenges in percutaneous coronary intervention due to the increased risk of restenosis, thrombosis and major adverse cardiac events (MACE). Determining the optimal stenting technique remains crucial to improving patient outcomes. Methods: This network meta-analysis systematically reviewed 19 eligible studies assessing diverse stenting strategies’ effects on MACE and target lesion revascularisation (TLR) at 12-month follow-up. Random effects models were used and studies were selected using the PICO framework – population, intervention, comparison, outcome. Key techniques evaluated included provisional single-stenting, double-stenting (culotte, T-stenting and small protrusion (T/TAP), V-stenting and standard crush) and double kissing (DK) crush. Quality and risk of bias were appraised using appropriate validated instruments. Results: DK crush demonstrated significantly lower TLR (RR 0.58; 95% CI [0.38–0.88]) and MACE (RR 0.51; 95% CI [0.36–0.72]) compared with single-stenting. Pooled double-stenting techniques increased TLR risk (RR 1.29; 95% CI [1.06–1.58]). Detailed ranking models consistently placed DK crush as the most effective, with p-values up to 0.95. Heterogeneity and reporting bias were minimal, supporting the robustness of these findings. Provisional stenting remains suitable for less complex bifurcations, while culotte and T/TAP were associated with higher risks. Conclusion: DK crush is the preferred strategy for complex LMBL as it minimises MACE and TLR. Provisional stenting is reasonable in simpler anatomical scenarios. Clinical decision-making should incorporate lesion complexity, patient characteristics and operator expertise. Further large-scale randomised trials are warranted to validate these results.

1 July 2026 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Closed access
SSSuryono Suryono
Suryono Suryono
MAMuhammad I. Amien
Muhammad I. Amien
ATAchmad I. Tohari
Achmad I. Tohari
Antonius Dwi SaputraAntonius Dwi Saputra
Antonius Dwi Saputra
MHMuhammad R. Fahrudin Hidayat
Muhammad R. Fahrudin Hidayat
MHMuhammad F. Hibatulloh
Muhammad F. Hibatulloh
Context: In-stent restenosis (ISR) remains a major complication following percutaneous coronary intervention. Increasing evidence suggests that genetic and inflammatory mechanisms contribute to ISR pathogenesis. Colchicine has demonstrated anti-inflammatory effects in cardiovascular diseases; however, its molecular targets in ISR remain unclear. Aims: To identify potential molecular targets and signaling pathways through which colchicine may modulate ISR using integrated computational approaches. Methods: ISR-related genes were retrieved from GeneCards, OMIM, and CTD databases. Colchicine targets were predicted using SwissTargetPrediction, BindingDB, SEASearch, and DrugBank. Overlapping genes were analyzed using protein–protein interaction networks and hub gene identification. Functional enrichment analysis was performed using GO and KEGG pathways. Molecular docking and 200 ns molecular dynamics simulations were conducted to evaluate binding stability. Binding free energies were calculated using MM-GBSA. Results: Sixteen overlapping targets were identified, and ten hub genes were prioritized. Docking analysis demonstrated moderate binding affinity of colchicine toward CYP3A4, TUBB1, and CYP2B6 (−6.9 to −7.4 kcal/mol). Molecular dynamics simulations indicated stable ligand–protein complexes with RMSD values below 2.5 Å. MM-GBSA analysis suggested favorable binding energies, particularly for TUBB1. Conclusions: Colchicine was predicted to interact with several ISR-associated targets and pathways, providing a computational basis for further experimental validation.

30 October 2026 in European Cardiology Review
Verified
Journal Article
Open access
SSSuryono Suryono
Suryono Suryono
MHMuhammad Farhan Hibatulloh
Muhammad Farhan Hibatulloh
ARAlfiyah Ramadhani
Alfiyah Ramadhani
CWCandra Agung Wibisana
Candra Agung Wibisana
MHMuhammad Naufal Hibatullah
Muhammad Naufal Hibatullah
HRHazbina Fauqi Ramadhan
Hazbina Fauqi Ramadhan
Background: Optimal antiplatelet therapy after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) requires balancing thrombotic protection and bleeding risk, but the comparative effectiveness of current strategies remains uncertain. Aims: To evaluate the risk–benefit profile of oral antiplatelet strategies after PCI with DES, focusing on major bleeding and stent thrombosis. Methods: A network meta-analysis of randomised and observational studies was conducted. Strategies included standard or extended dual antiplatelet therapy (DAPT), shortened DAPT followed by monotherapy and P2Y12 inhibitor-based monotherapy. Outcomes were analysed using a random-effects model and ranked with p-scores. Evidence certainty was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results: Thirty studies involving 110,035 patients were included. Ticagrelor monotherapy ranked highest for reducing major bleeding, whereas extended DAPT provided the greatest protection against stent thrombosis, with clopidogrel-based therapy beyond 12 months ranking highest (RR 0.08; 95% CI [0.01–0.52]; p-score=0.94). Notably, clopidogrel monotherapy after prolonged DAPT demonstrated a relatively balanced profile across both outcomes. However, no strategy was consistently optimal and most estimates showed wide CIs. Conclusion: Antiplatelet strategies after PCI with DES involve a clear trade-off between bleeding and thrombotic risk. Clopidogrel monotherapy after prolonged DAPT may offer a balanced approach, although findings should be interpreted cautiously due to limited precision and consistency.